enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given an average rating of “Buy” by the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $34.40.

ENGN has been the subject of several recent analyst reports. Morgan Stanley began coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective for the company. Guggenheim began coverage on shares of enGene in a research report on Monday, April 15th. They issued a “buy” rating and a $34.00 price target for the company. UBS Group began coverage on shares of enGene in a research report on Thursday, March 28th. They issued a “buy” rating and a $37.00 price target for the company. Wells Fargo & Company began coverage on shares of enGene in a research report on Monday, April 22nd. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th.

enGene Stock Up 4.7 %

Shares of NASDAQ:ENGN opened at $13.27 on Friday. enGene has a twelve month low of $6.69 and a twelve month high of $43.00. The business’s 50 day moving average is $15.76.

Insider Buying and Selling at enGene

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the business’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On enGene

Institutional investors have recently bought and sold shares of the company. Altitude Crest Partners Inc. purchased a new position in shares of enGene in the 1st quarter valued at about $2,039,000. Vivo Capital LLC purchased a new position in shares of enGene in the 4th quarter valued at about $6,264,000. Omega Fund Management LLC purchased a new position in shares of enGene in the 4th quarter valued at about $10,441,000. Janus Henderson Group PLC purchased a new position in shares of enGene in the 1st quarter valued at about $17,095,000. Finally, BVF Inc. IL purchased a new position in shares of enGene in the 4th quarter valued at about $20,777,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.